Sequence: cyclic RGD motif
| Experiment Id | EXP000673 |
|---|---|
| Paper | Direct Cytosolic Delivery of siRNA Conjugates: A Paradigm in Antiangiogenic Therapy for Choroidal Ne |
| Peptide | cRGD |
| Delivery Success Class | no |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | no |
| Peptide Concentration | covalent conjugate |
| Rna Concentration | intravitreal dose |
| Mixing Ratio | covalent |
| Formulation Format | siRNA conjugate |
| Formulation Components | RGD–siRNA–cholesteryl |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | laser-induced CNV mouse model |
| Administration Route | intravitreal |
| Output Type | angiogenesis inhibition |
| Output Value | Up to 67.3% CNV lesion reduction (TriRGD–F) |
| Output Units | |
| Output Notes | Fluorinated TriRGD system shows strongest in vivo efficacy |
| Toxicity Notes | No retinal toxicity observed |
| Curation Notes |